Exagen Inc is a diagnostics & research business based in the US. Exagen shares (XGN) are listed on the NASDAQ and all prices are listed in US Dollars. Exagen employs 181 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Exagen
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – XGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Exagen stock price (NASDAQ: XGN)Use our graph to track the performance of XGN stocks over time.
Exagen shares at a glance
|Latest market close||$13.74|
|52-week range||$10.31 - $23.18|
|50-day moving average||$14.53|
|200-day moving average||$16.18|
|Wall St. target price||$26.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-293.37|
Buy Exagen shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Exagen stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Exagen price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-8.52%|
|3 months (2021-04-30)||-18.51%|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
|Revenue TTM||$43 million|
|Gross profit TTM||$25.4 million|
|Return on assets TTM||-8.74%|
|Return on equity TTM||-22.81%|
|Market capitalisation||$201.8 million|
TTM: trailing 12 months
Shorting Exagen shares
There are currently 429,834 Exagen shares held short by investors – that's known as Exagen's "short interest". This figure is 4.7% down from 451,025 last month.
There are a few different ways that this level of interest in shorting Exagen shares can be evaluated.
Exagen's "short interest ratio" (SIR)
Exagen's "short interest ratio" (SIR) is the quantity of Exagen shares currently shorted divided by the average quantity of Exagen shares traded daily (recently around 93442.173913043). Exagen's SIR currently stands at 4.6. In other words for every 100,000 Exagen shares traded daily on the market, roughly 4600 shares are currently held short.
However Exagen's short interest can also be evaluated against the total number of Exagen shares, or, against the total number of tradable Exagen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exagen's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Exagen shares in existence, roughly 30 shares are currently held short) or 0.0511% of the tradable shares (for every 100,000 tradable Exagen shares, roughly 51 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Exagen.
Find out more about how you can short Exagen stock.
Exagen share dividends
We're not expecting Exagen to pay a dividend over the next 12 months.
Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.
Stocks similar to Exagen
Exagen in the news
Exagen Appoints Ana Hooker to Board of Directors
Exagen Appoints Ana Hooker to Board of Directors
Exagen appoints Ana Hooker to board of directors
Frequently asked questionsWhat percentage of Exagen is owned by insiders or institutions?
Currently 21.682% of Exagen shares are held by insiders and 74.911% by institutions. How many people work for Exagen?
Latest data suggests 181 work at Exagen. When does the fiscal year end for Exagen?
Exagen's fiscal year ends in December. Where is Exagen based?
Exagen's address is: 1261 Liberty Way, Vista, CA, United States, 92081 What is Exagen's ISIN number?
Exagen's international securities identification number is: US30068X1037 What is Exagen's CUSIP number?
Exagen's Committee on Uniform Securities Identification Procedures number is: 30068X103
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert